Neovacs SA banner

Wall St Price Targets

0LW Price Targets Summary
Neovacs SA

There are no price targets for 0LW.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Neovacs SA Competitors:
Price Targets
UFPT
UFP Technologies Inc
7% Upside
VERK
Verkkokauppa.com Oyj
11% Upside
PRQR
ProQR Therapeutics NV
304% Upside
CIGI
Colliers International Group Inc
-1% Downside
HCAT
Health Catalyst Inc
41% Upside

Revenue
Forecast

N/A
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss

The compound annual growth rate for Revenue over the next 8 years is 25%.

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
8%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
8%
Average Beat

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 0LW's stock price target?
Not Available

0LW does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Neovacs SA?
Projected CAGR
25%

The compound annual growth rate for Revenue over the next 8 years is 25%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett